Multi-Omic RA Biomarkers for Seronegative Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for rheumatoid arthritis (RA) have low sensitivity and specificity, particularly for seronegative RA patients who lack anti-citrullinated protein antibodies (ACPA−), limiting early diagnosis and effective treatment.
Innovation Solution
A multi-omic analysis approach integrating proteomics, metabolomics, and autoantibody profiling, combined with machine learning, to identify specific biomarkers for ACPA− and ACPA+ RA subtypes, enabling accurate diagnosis and treatment based on plasma samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional serological tests (RF and ACPA) are used for RA diagnosis, then specificity is improved (ACPA specificity ~95%), but sensitivity deteriorates for seronegative patients (detecting only 70-80% of RA cases)
Solution Approach 1:
The patent combines multiple serological markers (RF, ACPA, anti-carbamylated protein antibodies, anti-transglutaminase antibodies) into a composite diagnostic panel. This merging of multiple detection targets allows the system to maintain high specificity through multiple confirmatory markers while improving sensitivity by detecting diverse antibody profiles across different patient subgroups, including seronegative cases.
Solution Approach 2:
The diagnostic system is designed to serve multiple functions: it detects both seropositive and seronegative RA patients, differentiates between RA subtypes, and provides prognostic information. By creating a universal diagnostic platform that handles diverse clinical presentations through a single multi-marker assay system, the patent resolves the contradiction between maintaining high specificity and achieving broad sensitivity.
2Measurement precision
If ACPA testing is performed to identify specific RA subtypes, then diagnostic specificity is improved, but the ability to diagnose seronegative RA deteriorates (ACPA− patients are missed)
Solution Approach 1:
The patent segments the RA patient population into distinct subgroups (ACPA+, RF+, ACPA−/RF−, and other seronegative subtypes) and develops specific marker panels for each segment. This segmentation allows the diagnostic system to maintain high specificity for ACPA+ patients while simultaneously providing diagnostic coverage for seronegative patients through alternative marker detection, thus resolving the contradiction between specificity and adaptability.
Solution Approach 2:
The system changes the检测 parameters by switching from detecting only ACPA to detecting multiple antibody classes (IgG, IgM, IgA) against various antigens (citrullinated proteins, carbamylated proteins, transglutaminase). This parameter expansion allows the diagnostic platform to adapt to different patient phenotypes while maintaining rigorous specificity criteria through multi-marker confirmation.
3Reliability
If multiple serological markers are tested to improve sensitivity, then diagnostic coverage is improved, but test complexity increases
Solution Approach 1:
The patent merges multiple individual serological tests into a single integrated multi-marker assay platform. By combining detection of RF, ACPA, anti-carbamylated protein antibodies, and anti-transglutaminase antibodies into one coordinated system, the patent achieves high sensitivity through comprehensive marker detection while managing complexity through system integration and automated interpretation algorithms.
4Measurement precision
If comprehensive multi-omic analysis is performed to identify biomarkers, then diagnostic accuracy is improved, but analysis complexity and cost increase
Solution Approach 1:
The patent extracts and focuses on specific high-value biomarkers (anti-carbamylated protein antibodies, anti-transglutaminase antibodies) from the broader multi-omic landscape. Rather than analyzing all possible omic layers, the system selectively isolates and measures the most diagnostically relevant markers, thereby maintaining high diagnostic accuracy while reducing analysis complexity and computational burden.
Data Source
AI summary
The disclosure generally relates to methods of selecting a biomarker associated with a disorder or disease, and computer program products and systems for performing such methods. The disclosure further relates to biomarkers for rheumatoid arthritis and methods of use such biomarkers.